

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康臣藥業集團有限公司**  
CONSUN PHARMACEUTICAL GROUP LIMITED

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1681)**

## **Voluntary Announcement Drug Registration Approval for Iopromide Injection**

This announcement is made by Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide its shareholders and potential investors with the updates on the development of the business of the Group.

### **Drug Registration Approval for Iopromide Injection**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 30 July 2024, the iopromide injection (the “**Product**”) developed by Guangzhou Consun Pharmaceutical Company Limited\* (廣州康臣藥業有限公司) (an indirectly wholly-owned subsidiary of the Company) has obtained drug registration approvals granted by the National Medical Products Administration, which was deemed to have passed the generic drug consistency evaluation with two specifications of 100ml: 62.34g and 100ml: 76.89g.

The Product is a non-ionic, low osmolar and low viscosity contrast agent used for X-ray computed tomography (CT) enhancement in blood vessels and body cavities, arteriography and venography, intra-arterial/intravenous digital subtraction angiography (DSA), intravenous urography, endoscopic retrograde cholangiopancreatography (ERCP), arthrography and other body cavity examinations.

Compared with the marketed low osmolar contrast agents, the Product has a relatively low viscosity. It has the characteristics of comfortable injection, high water solubility and high safety for patients. With its high concentration property, its clinical application can increase image contrast and improve the accuracy of imaging examinations. By virtue of the high concentration and low viscosity properties, the Product has been confirmed by evidence-based medicine that it has high cardiac and renal safety, and has a favourable market prospect.

The approval of the Product will enable the Group to form a product portfolio for low osmolar and isotonic CT contrast agents with varying concentrations. It can also enrich customers’ drug choices and contribute to the development of the Group in the medical contrast medium field.

**As there are significant risks and uncertainties in the process of research, development and commercialization of pharmaceutical product, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company. The Company will actively pursue the above-mentioned research and development project and will comply with its obligations to disclose information on the subsequent progress of the project in a timely manner in strict accordance with the relevant regulations.**

By Order of the Board  
**Consun Pharmaceutical Group Limited**  
**An Meng**  
*Chairman*

Hong Kong, 7 August 2024

*As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Ms. Chen Yujun and Professor Li Yikai as independent non-executive Directors.*

\* *for identification only*